Victory Capital Management Inc. Has $32.21 Million Stock Holdings in AstraZeneca PLC (NASDAQ:AZN)

Victory Capital Management Inc. increased its holdings in AstraZeneca PLC (NASDAQ:AZN - Free Report) by 8.4% in the first quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 438,193 shares of the company's stock after buying an additional 34,123 shares during the period. Victory Capital Management Inc.'s holdings in AstraZeneca were worth $32,207,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other large investors also recently bought and sold shares of the business. Principal Securities Inc. raised its stake in AstraZeneca by 0.5% during the 1st quarter. Principal Securities Inc. now owns 28,053 shares of the company's stock worth $2,062,000 after acquiring an additional 142 shares in the last quarter. Sage Mountain Advisors LLC raised its stake in AstraZeneca by 3.4% during the 1st quarter. Sage Mountain Advisors LLC now owns 4,478 shares of the company's stock worth $329,000 after acquiring an additional 147 shares in the last quarter. CoreCap Advisors LLC raised its stake in AstraZeneca by 31.8% during the 4th quarter. CoreCap Advisors LLC now owns 642 shares of the company's stock worth $42,000 after acquiring an additional 155 shares in the last quarter. Oakworth Capital Inc. increased its stake in AstraZeneca by 2.0% in the first quarter. Oakworth Capital Inc. now owns 8,575 shares of the company's stock valued at $630,000 after purchasing an additional 167 shares during the period. Finally, Spinnaker Investment Group LLC increased its stake in AstraZeneca by 3.1% in the first quarter. Spinnaker Investment Group LLC now owns 5,754 shares of the company's stock valued at $423,000 after purchasing an additional 174 shares during the period. Institutional investors own 20.35% of the company's stock.

AstraZeneca Stock Up 2.6%

Shares of AZN stock traded up $1.76 during trading on Tuesday, hitting $70.48. 3,124,719 shares of the company were exchanged, compared to its average volume of 5,269,037. The company has a debt-to-equity ratio of 0.65, a quick ratio of 0.70 and a current ratio of 0.90. The firm has a market capitalization of $218.58 billion, a price-to-earnings ratio of 28.31, a P/E/G ratio of 1.26 and a beta of 0.37. The business's 50-day simple moving average is $70.78 and its 200 day simple moving average is $70.99. AstraZeneca PLC has a twelve month low of $61.24 and a twelve month high of $87.68.

AstraZeneca (NASDAQ:AZN - Get Free Report) last posted its quarterly earnings results on Tuesday, April 29th. The company reported $1.24 EPS for the quarter, topping the consensus estimate of $1.10 by $0.14. The business had revenue of $13.59 billion during the quarter, compared to analysts' expectations of $13.71 billion. AstraZeneca had a net margin of 14.14% and a return on equity of 33.14%. The firm's quarterly revenue was up 7.2% compared to the same quarter last year. During the same period last year, the company posted $2.06 earnings per share. As a group, analysts forecast that AstraZeneca PLC will post 4.51 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of analysts recently commented on AZN shares. Berenberg Bank set a $97.00 price objective on shares of AstraZeneca in a report on Wednesday, July 9th. BNP Paribas started coverage on shares of AstraZeneca in a research report on Tuesday, April 15th. They set an "outperform" rating and a $75.00 target price for the company. One equities research analyst has rated the stock with a hold rating and five have given a buy rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $89.00.

AstraZeneca Profile

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.